BioXcell特色抗体之：CD Marker
时间：2023-01-19 16:26:51 浏览次数：218
分享：
| Antigen | Reactivity | Application | Clone | CloneInVivoMab Catalog | InVivoPlus Catalog |
| CD1a | human | in vitro CD1a blockade, FC | OKT-6 | BE0211 | |
| CD1d (CD1.1) | mouse | in vivo CD1d neutralization | 19G11 | BE0000 | |
| CD1d (CD1.1) | mouse | iNKT cell neutralization, in vivo CD1d blockade, FC | 20H2 (HB323) | BE0179 | |
| CD3 | human | in vitro T cell stimulation/activation, in vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC | OKT-3 | BE0001-2 | |
| CD3 | mouse | in vitro T cell stimulation/activation | 17A2 | BE0002 | |
| CD3 | human |
in vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC |
UCHT1 (Leu-4) (T3) | BE0231 | |
| CD3ɛ | mouse |
in vivo T cell depletion, in vitro T cell stimulation/activation, IF, FC |
145-2C11 | BE0001-1 | BP0001-1 |
| CD3ɛ | mouse | in vitro T cell negative selection, in vitro T cell stimulation/activation, IF | KT3 | BE0261 | |
| CD3ɛ F(ab')2 fragment | mouse | in vivo T cell depletion | 145-2C11 f(ab')2 Fragments | BE0001-1FAB | |
| CD4 | mouse | in vivo CD4+ T cell depletion, FC | GK1.5 | BE0003-1 | BP0003-1 |
| CD4 | human | in vitro T cell stimulation/activation, in vivo CD4+ T cell depletion in humanized mice, FC, IP | OKT-4 | BE0003-2 | |
| CD4 | mouse | in vivo blockade of CD4+ T-cell responses, WB | YTS 177 | BE0003-3 | |
| CD4 | mouse | in vivo CD4+ T cell depletion | YTS 191 | BE0119 | |
| CD4 | human | in vitro CD4 blockade, in vitro blocking of CD4+ T cell activation, IF, IHC-F, FC | RPA-T4 | BE0288 | |
| CD4 | rat | in vivo CD4+ T cell depletion, FC | OX-38 | BE0308 | |
| CD8 (Lyt 2.1) | mouse | in vivo CD8+ T cell depletion, FC | 116-13.1 (HB129) | BE0118 | |
| CD8α | mouse | in vivo CD8+ T cell depletion, IF, FC | 53-6.7 | BE0004-1 | BP0004-1 |
| CD8α | human | in vivo CD8+ T cell depletion in humanized mice | OKT-8 | BE0004-2 | |
| CD8α | mouse | in vivo CD8+ T cell depletion | 2.43 | BE0061 | BP0061 |
| CD8α | mouse | in vivo CD8+ T cell depletion | YTS169.4 | BE0117 | BP0117 |
| CD8β (Lyt 3.2) | mouse | in vivo CD8+ T cell depletion, in vitro CD8 blockade, IF | 53-5.8 | BE0223 | |
| CD11a (LFA-1α) | human | in vitro LFA-1 neutralization | TS-1/22.1.1.13 | BE0005 | |
| CD11a (LFA-1α) | mouse | in vivo LFA-1 neutralization | FD441.8 | BE0005-1 | |
| CD11a (LFA-1α) | mouse | in vivo LFA-1 neutralization, FC | M17/4 | BE0006 | |
| CD11a (LFA-1α) | human | Functional assays, FC | R7-1 | BE0192 | |
| CD11b | mouse/human | in vivo CD11b neutralization, ILC2 cell purification, FC | M1/70 | BE0007 | |
| CD16/CD32 | mouse | in vivo and in vitro Fc receptor blocking | 2.4G2 | BE0307 | |
| CD18 | mouse | in vivo LFA-1 neutralization | M18/2 | BE0009 | |
| CD19 | mouse | in vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, FC | 1D3 | BE0150 | |
| CD19 | human | FC, Functional assays, IF, Chimeric antigen receptor construction | 4G7 | BE0281 | |
| CD20 | mouse | in vivo B cell depletion, WB | MB20-11 | BE0356 | BP0356 |
| CD20 | human/monkey | in vivo B cell depletion in hCD20 Tg mice, IHC-F, IP, FC | 2H7 | BE0276 | |
| CD20 | mouse | FC, WB | AISB12 | BE0302 | |
| CD22 | mouse | in vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), FC, IP | Cy34.1 | BE0011 | |
| CD24 | mouse | in vivo administration, IHC-F, IHC-P, IF, FC | M1/69 | BE0360 | |
| CD25 (IL-2Rα) | mouse | in vivo regulatory T cell depletion, FC | PC-61.5.3 | BE0012 | BP0012 |
| CD25 (IL-2Rα) | human | IP,IF | 7G7B6 | BE0014 | |
| CD27 | mouse | in vivo CD27 stimulation, in vitro CD27 stimulation, IP, FC | RM27-3E5 | BE0348 | |
| CD28 | mouse | in vivo CD28 blockade, in vitro T cell stimulation/activation | 37.51 | BE0015-1 | |
| CD28 | mouse | in vitro T cell stimulation/activation | PV-1 | BE0015-5 | |
| CD28 | rat | in vitro T cell stimulation/activation, FC | JJ319 | BE0040 | |
| CD28 | human | in vitro T cell stimulation/activation | 9.3 | BE0248 | |
| CD28 | human/monkey | in vitro T cell stimulation/activation, FC, IHC-F, IP | CD28.2 | BE0291 | |
| CD28 | mouse | in vivo and in vitro T cell stimulation/activation | D665 | BE0328 | |
| CD29 | mouse | IF, FC | KMI6 | BE0232 | |
| CD32 (FcγRIIA) | human | in vivo FcγRIIA blockade in humanized mice, in vitro FcγRIIA blockade, ELISA, FC | IV.3 | BE0224 | |
| CD38 | mouse | in vivo and in vitro CD38 stimulation, in vitro B cell activation, IF | NIMR5 | BE0317 | |
| CD40 | mouse | in vivo CD40 activation, in vitro B cell stimulation/activation | FGK4.5/FGK45 | BE0016-2 | BP0016-2 |
| CD40 | human | in vitro B cell stimulation, in vitro CD40 stimulation, in vitro macrophage stimulation, Functional assays, FC | G28.5 | BE0189 | |
| CD154 (CD40L) | mouse | in vivo and in vitro blocking of CD40/CD40L signaling | MR-1 | BE0017-1 | BP0017-1 |
| CD154 (CD40L) | human/monkey | in vitro blocking of CD40/CD40L signaling, in vivo blocking of CD40/CD40L signaling, IP, FC | 5C8 | BE0292 |
| Antigen | Reactivity | Application | Clone | CloneInVivoMab Catalog | InVivoPlus Catalog |
| CD44 | mouse/human | in vivo CD44 neutralization |
IM7 |
BE0039 | |
| CD44 | human | in vivo CD44 blockade in xenografts, in vitro CD44 blockade, WB, IF |
Hermes-1 |
BE0262 | |
| CD45RB | mouse | in vivo anti-CD45RB–mediated tolerance induction, in vivo pre-mNK cell depletion |
MB23G2 (HB220) |
BE0019 | |
| CD45.2 | mouse | in vivo and in vitro CD45.2 blockade, FC, IHC-F, |
104.2 |
BE0300 | |
| CD47 | human | in vivo CD47 neutralization in human tumor xenograft models or humanized mice, in vitro CD47 neutralization, FC |
B6H12 |
BE0019-1 | |
| CD47 | human/mouse/rat | in vivo and in vitro CD47 blockade, IF |
MIAP410 |
BE0283 | BP0283 |
| CD47 (IAP) | mouse | in vivo CD47 blockade, in vitro CD47 blockade, IF |
MIAP301 |
BE0270 | |
| CD48 | mouse | in vivo and in vitro CD48 blockade |
HM48-1 |
BE0147 | |
| CD49d (VLA-4) | mouse/human | in vivo and in vitro VLA-4 neutralization, FC |
PS/2 |
BE0071 | |
| CD54 (ICAM-1) | mouse | In vivo ICAM-1 neutralization |
YN1/1.7.4 |
BE0020-1 | |
| CD54 (ICAM-1) | human | in vitro T cell stimulation/activation, IF |
R6-5-D6 |
BE0020-2 | |
| CD62E (E-Selectin) | mouse | in vivo and in vitro E-selectin blockade, IHC-F |
9A9 |
BE0294 | |
| CD62L (L-Selectin) | mouse | In vivo CD62L neutralization |
Mel-14 |
BE0021 | |
| CD69 | mouse | in vivo down-regulation of CD69 expression, Functional assays |
CD69.2.2 |
BE0330 | |
| CD70 | mouse | in vivo and in vitro CD70 blockade, FC |
FR70 |
BE0022 | |
| CD71 | human | FC, IHC-F |
OKT9 |
BE0023 | |
| CD71 (TfR) | human | WB, IP, FC |
5E9C11 |
BE0343 | |
| CD71 (TfR1) | mouse | in vivo depletion of CD71+ cells |
R17 217.1.3/TIB-219 |
BE0175 | |
| CD71 (TfR1) | mouse | in vivo depletion of CD71+ cells, IF, IHC-F, WB |
8D3 |
BE0329 | |
| CD71 (TfR1) | rat/mouse | Targeted drug delivery to the brain, IHC-F, FC |
OX-26 |
BE0331 | |
| CD73 | mouse | in vivo CD73 blockade |
TY/23 |
BE0209 | |
| CD80 (B7-1) | mouse | in vivo B7-1 blockade, affinity chromatography |
1G10 |
BE0134 | |
| CD80 (B7-1) | mouse | In vivo CD80 blockade, FC |
16-10A1 |
BE0024 | |
| CD86 (B7-2) | mouse | In vivo CD86 blockade, FC |
GL-1 |
BE0025 | |
| CD90 (Thy1) | mouse | in vitro T cell depletion |
M5/49.4.1 |
BE007 | |
| CD90.1 (Thy1.1) | mouse | in vivo T cell depletion |
19E12 |
BE0214 | |
| CD90.2 (Thy1.2) | mouse | in vivo ILC depletion, in vivo T cell depletion |
30H12 |
BE0066 | BP0066 |
| CD91 (LRP1) | mouse/human/rat | WB, IF, IP |
11H4 |
BE0333 | |
| CD96 | mouse | in vivo and in vitro CD96 blocking, FC |
3.3 |
BE0337 | |
| CD103 | mouse | In vivo CD103 neutralization, IF, FC |
M290 |
BE0026 | |
| CD106 (VCAM-1) | mouse | in vivo VCAM-1 neutralization, IF |
M/K-2.7 |
BE0027 | |
| CD115 (CSF1R) | mouse | in vivo macrophage depletion, in vivo monocyte depletion, in vitro CSF-R1 neutralization, FC |
AFS98 |
BE0213 | BP0213 |
| CD115 (CSF1R) | human | in vitro CSF1R neutralization, IHC-P, FC, Functional assays | 2-4A5-4 | BE0347 | |
| CD117 (c-Kit) | mouse | FC, IF, IHC |
2B8 |
BE0280 | |
| CD119 (IFNγR) | mouse | in vivo IFNγR neutralization |
GR-20 |
BE0029 | |
| CD119 (IFNγRα) | mouse | WB, IP, FC |
2E2 |
BE0287 | |
| CD120b (TNFR2) | mouse | in vivo TNFR2 blockade, in vitro TNFR2 blockade |
TR75-54.7 |
BE0247 | |
| CD121a (IL-1 R) | mouse | in vitro IL-1 R blockade |
JAMA-147 |
BE0256 | |
| CD122 (IL-2Rβ) | mouse | in vitro NK cell negative selection, IP, FC |
5H4 |
BE0272 | |
| CD122 (IL-2Rβ) | mouse | in vivo NK cell depletion, in vitro IL-2R blockade, Functional assays, FC |
TM-Beta 1 |
BE0298 | |
| CD127 (IL-7Rα) | mouse | in vivo blocking of IL-7Rα signaling, FC |
A7R34 |
BE0065 | |
| CD132 (common γ chain) | mouse | in vivo γc blockade, Functional assays, IP, FC |
3E12 |
BE0271 | |
| CD134 (OX40) | mouse | in vivo and in vitro OX40 activation |
OX-86 |
BE0031 | BP0031 |
| CD134L (OX40L) | mouse | in vivo blocking of OX40/OX40L signaling, in vitro OX40L neutralization |
RM134L |
BE0033-1 | |
| CD137 (4-1BB) | mouse | in vivo activation of 4-1BB |
LOB12.3 |
BE0169 | BP0169 |
| CD137 (4-1BB) | mouse | in vivo and in vitro 4-1BB stimulation |
3H3 |
BE0239 | BP0239 |
| CD137 (4-1BB) | mouse | in vitro 4-1BB blockade, FC |
17B5 |
BE0296 | |
| CD137L (4-1BBL) | mouse | in vivo 4-1BBL blockade |
TKS-1 |
BE0110 | |
| CD152 (CTLA-4) | mouse | in vivo and in vitro CTLA-4 neutralization, FC |
UC10-4F10-11 |
BE0032 | BP0032 |
| CD152 (CTLA-4) | mouse | in vivo and in vitro CTLA-4 neutralization, FC |
9H10 |
BE0131 | BP0131 |
| CD152 (CTLA-4) | mouse | in vivo CTLA-4 neutralization |
9D9 |
BE0164 | BP0164 |
| Antigen | Reactivity | Application | Clone | CloneInVivoMab Catalog | InVivoPlus Catalog |
| CD152 (CTLA-4) | human | in vitro CTLA-4 neutralization, FC |
BN13 |
BE0190 | |
| CD159 (NKG2A/C/E) | mouse | in vivo and in vitro NKG2A blockade, IHC-F, FC |
20D5 |
BE0321 | |
| CD161 (NK1.1) | mouse | in vivo NK cell depletion, FC |
PK136 |
BE0036 | BP0036 |
| CD162 (PSGL-1) | mouse | in vivo PSGL-1 blockade, IHC-F |
4RA10 |
BE0186 | |
| CD172a (SIRPα) | mouse | in vivo and in vitro SIRPα blocking, WB, IP, FC |
P84 |
BE0322 | |
| CD178 (FasL) | mouse | in vivo and in vitro FasL blockade, Functional assay, IHC-P, FC |
MFL3 |
BE0319 | |
| CD183 (CXCR3) | mouse | in vivo CXCR3 neutralization, FC |
CXCR3-173 |
BE0249 | |
| CD193 (CCR3) | mouse | in vivo eosinophil depletion |
6S2-19-4 |
BE0316 | |
| CD200 (OX2) | mouse | in vivo and in vitro CD200 blockade, IHC-F, IF, FC |
OX-90 |
BE0299 | |
| CD209b (SIGN-R1) | mouse | in vivo SIGN-R1 blockade, IHC-F, WB, FC |
22D1 |
BE0220 | |
| CD210 (IL-10R) | mouse | in vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, FC |
1B1.3A |
BE0050 | BP0050 |
| CD220 (Insulin Receptor) | human | WB |
IR 83-22 |
BE0338 | |
| CD223 (LAG-3) | mouse | in vivo and in vitro LAG-3 neutralization, FC |
C9B7W |
BE0174 | BP0174 |
| CD227 (MUC1) | human | in vivo administration in mouse xenograft models, in vitro cell cytotoxicity assay, WB, IHC-P, IF, |
C595 (NCRC48) |
BE0336 | |
| CD243 (MDR-1) | human/monkey | in vivo MDR-1 blocking/depletion in xenogeneic murine tumor models, in vitro MDR-1 blocking, IHC-P |
UIC2 |
BE0340 | |
| CD254 (RANKL) | mouse | in vivo RANKL blockade |
IK22/5 |
BE0191 | |
| CD262 (DR5) | mouse | in vivo and in vitro induction TRAIL-mediated apoptosis |
MD5-1 |
BE0161 | |
| CD272 (BTLA) | mouse | in vivo BTLA stimulation, in vivo BTLA blockade |
6A6 |
BE0132 | |
| CD272 (BTLA) | mouse | in vivo and in vitro stimulation of BTLA, FC |
PK18.6 |
BE0153 | |
| CD272 (BTLA) | mouse | in vivo BTLA blockade, in vitro T cell stimulation/activation, FC |
PJ196 |
BE0196 | |
| CD272 (BTLA) | mouse | in vivo BTLA+ B cell and CD4 T cell depletion, FC |
6F7 |
BE0304 | |
| CD273 (PD-L2) | mouse | in vivo and in vitro PD-L2 blockade, IHC-F, FC |
TY25 |
BE0112 | |
| CD274 (PD-L1) | mouse | in vivo PD-L1 blockade, IF, IHC-F, FC |
10F.9G2 |
BE0101 | BP0101 |
| CD275 (ICOSL) | mouse | in vivo ICOSL neutralization |
HK5.3 |
BE0028 | |
| CD276 (B7-H3) | mouse | in vivo B7-H3 blockade, FC |
MJ18 |
BE0124 | |
| CD278 (ICOS) | mouse | in vivo blocking of ICOS/ICOSL signaling, FC |
7E.17G9 |
BE0059 | |
| CD279 (PD-1) | mouse | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization |
J43 |
BE0033-2 | BP0033-2 |
| CD279 (PD-1) | mouse | in vivo blocking of PD-1/PD-L signaling |
RMP1-14 |
BE0146 | BP0146 |
| CD279 (PD-1) | human | in vitro PD-1 neutralization, in vivo PD-1 blockade in humanized mice |
J116 |
BE0188 | |
| CD279 (PD-1) | human | in vivo PD-1 blockade in humanized mice, FC |
J110 |
BE0193 | |
| CD279 (PD-1) | mouse | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, IHC-F, FC, WB |
29F.1A12 |
BE0273 | BP0273 |
| CD314 (NKG2D) | mouse | in vivo and in vitro NKG2D blockade, FC |
CX5 |
BE0334 | |
| CD317 (BST2, PDCA-1) | mouse | in vivo pDC depletion, IF, FC |
927 |
BE0311 | |
| CD324 (E-Cadherin) | mouse | in vivo E-Cadherin neutralization, in vitro E-Cadherin neutralization, IF, IP, WB |
DECMA-1 |
BE0352 | |
| CD326 (EpCAM) | mouse | WB, IF, IHC-F, FC |
G8.8 |
BE0346 | |
| CD340 HER2 (neu) | human/rat | in vivo and in vitro HER2/neu inhibition, IP, IF, FC |
7.16.4 |
BE0277 | |
| CD365 (TIM-1) | mouse | in vivo TIM-1 neutralization |
RMT1-10 |
BE0113 | |
| CD366 (TIM-3) | mouse | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, FC |
RMT3-23 |
BE0115 | BP0115 |
| CD366 (TIM-3) | mouse | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, FC |
B8.2C12 |
BE0275 | |
| CD370 (CLEC9A) | mouse | in vivo Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC |
7H11 |
BE0305 |
更多产品详情请咨询 BioXcell 中国授权代理——上海优宁维生物科技股份有限公司
上海优宁维生物科技股份有限公司
试剂 | 耗材 | 仪器 | 软件 | 定制 | 实验服务 | 供应链
免费热线：4008-168-068
咨询邮箱：info@univ-bio.com
订购商城：www.univ-bio.com
微信公众平台：优宁维抗体专家，欢迎关注！
小优博士（小程序）：5大课堂, 让你的科研不再难！
危险品化学品经营许可证(不带存储) 许可证编号：沪(杨)应急管危经许[2022]202944(QY) 
营业执照(三证合一)